Screening of Pim kinase inhibitors by the establishment of high-throughput ELISA system

尚琨; 张鹏; 周璐; 王瑧; 曹越; 李影奕

doi:10.3969/j.issn.1007-3969.2013.04.004

您当前的位置：

首页 >

文章列表页 >

Screening of Pim kinase inhibitors by the establishment of high-throughput ELISA system

更新时间：2025-12-31

- Screening of Pim kinase inhibitors by the establishment of high-throughput ELISA system
- China Oncology Vol. 23, Issue 4, Pages: 260-266(2013)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院实验研究中心，复旦大学上海医学院肿瘤学系,上海,200032
  2. 复旦大学药学院,上海,201203
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.04.004
  CLC：
- Published Online：19 November 2014，
  
  Published：2013
- 稿件说明：
移动端阅览
尚琨,张鹏,周璐,王瑧,曹越,李影奕. ELISA高通量筛选PIM靶向抑制剂的研究[J]. 中国癌症杂志, 2013, 23(4): 260-266.

尚琨, 张鹏, 周璐, et al. Screening of Pim kinase inhibitors by the establishment of high-throughput ELISA system[J]. China Oncology, 2013, 23(4): 260-266.
尚琨,张鹏,周璐,王瑧,曹越,李影奕. ELISA高通量筛选PIM靶向抑制剂的研究[J]. 中国癌症杂志, 2013, 23(4): 260-266. DOI： 10.3969/j.issn.1007-3969.2013.04.004.

尚琨, 张鹏, 周璐, et al. Screening of Pim kinase inhibitors by the establishment of high-throughput ELISA system[J]. China Oncology, 2013, 23(4): 260-266. DOI： 10.3969/j.issn.1007-3969.2013.04.004.

摘要

背景与目的：Pim家族是具有丝氨酸/苏氨酸激酶活性的原癌基因，包括Pim-1、Pim-2、Pim-3。研究发现，Pim能够抑制细胞凋亡，促进细胞增殖，导致肿瘤发生。本研究利用ELISA反应原理建立高通量筛选体系，对Pim抑制剂进行筛选，为药物的应用和解决恶性肿瘤临床治疗的难题提供研究基础。方法：通过计算机辅助药物设计的手段，以蔓生百部碱母核三环酰胺作为核心结构合成系列衍生物；利用Pim重组蛋白和Bad重组蛋白可以与Ni2+特异性结合的亲和层析原理进行重组蛋白的纯化精制；利用ELISA方法，通过Pim激酶磷酸化促凋亡蛋白分子Bad在112位丝氨酸的反应，建立筛选Pim靶向抑制剂的体系。结果：0.01 mmol/L的IPTG在37 ℃条件下，诱导Bad蛋白2 h，可以获得最大量的可溶性Bad重组蛋白；0.02%的阿拉伯糖在37 ℃条件下，诱导Pim-1、Pim-2、Pim-3蛋白3 h，可以获得最大量的Pim重组蛋白；ELISA结果显示，Pim激酶与Bad底物之间的作用存在剂量依赖性反应关系，进而成功建立药物筛选体系；初步筛选出低分子化合物T-18，在体外能有效抑制Pim激酶活性。结论：利用ELISA反应原理建立的筛选药物方法，是一种经济、简单、快速、高效、敏感的筛选手段，并初步筛选出小分子化合物T-18，能够抑制Pim激酶活性，阻断Pim对凋亡蛋白分子Bad的磷酸化过程，进而抑制肿瘤的发生。

Abstract

Background and purpose: Pim family is the proto-oncogene that exhibits serine/threonine kinase activity

containing Pim-1

Pim-2

Pim-3. Pim family has potent anti-apoptotic capacity

ultimately promoting tumor cells survival. This study aimed to establish a high-throughput system to screen the anti-cancer drugs targeting Pim kinase by ELISA. Methods: The stemonamide synthetic intermediates were synthesized using a radical cascade. The expression of Pim kinase proteins and Bad proteins were purified by bacterial system. A high-throughput ELISA screening was performed for in vitro Pim kinase assay. Results: Treatment with 0.01 mmol/L of IPTG for 2 hours at 37 ℃

the induction of Bad recombinant proteins was the maximum; Treatment with 0.02% of arabinose for 3 hours at 37 ℃

the induction of Pim-1

Pim-2

Pim-3 recombinant proteins was the maximum. ELISA results showed that the Pim kinase could phosphorylate Bad in a dose-dependent manner; we had found a low molecular weight compounds T-18

which could effective inhibit Pim kinase activity in vitro. Conclusion: We successfully established a screening system with Bad and Pim by ELISA. ELISA is a method for screening drug with high throughput

effect and sensitivity. Moreover

small molecule the compound T-18 that is screened by ELISA

can inhibit Pim kinase activities

ultimately reduce the amount of phosphorylated Bad and could induce apoptosis.

关键词

Keywords

references

Views

2585

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application of organoids in drug screening of gynecological malignant tumors

Application of 3D bioprinting in cancer research and tissue engineering

Recent progress in the construction and application of patient-derived pancreatic cancer organoid models

Integrated single-cell sequencing and transcriptome sequencing to reveal a 9-gene prognostic signature of immune cells in colorectal cancer

Application and progress of organoids in tumor translational medicine

Related Author

Yuanyuan JIANG

Wenfei WEI

Jingya WU

Huawen LI

Min TANG

Xin LUAN

Yan LI

Yahui DING

Related Institution

The First Clinical Medical College, Guangdong Medical University

Department of Gynecology, Zhuhai Clinical Medical College of Jinan University (Zhuhai People’s Hospital)

Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine

Institute of Integrative Medicine, Fujian University of Traditional Chinese Medicine

Key Laboratory of Integrative Medicine for Geriatric Diseases of Fujian Province

AI问答

⁰